Allergan, Inc.

Allergan Sales, Inc.

Chin-Ming Chang

James Nienyuan Chang

Rhett M Schiffman

Joan-En Chang-Lin

R Scott Jordan

Gary J Beck

Amy L Batoosingh

Cynthia C Pratt

Patrick Michael Hughes

Richard S Graham

Robert T Lyons

Eldon Q Farnes

Orest Olejnik

Anuradha V Gore

Teresa H Kuan

Joseph G Vehige

Bruce A Firestone

Kevin S Warner

Mayssa Attar

Janet K Cheetham

Jie Shen

Devin F Welty

Rodney J Terwilliger

John Jacob Vander Zanden

Sesha Neervannan

Richard Kurjan

J Abraham M Le Espiritu

Chetan P Pujara

Eldon Quinn Farnes

Jim Jiao

Linda Villanueva

David Hollander

Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.

Oil-in-water method for making polymeric implants containing a hypotensive lipid

Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

Combination of brimonidine and timolol for topical ophthalmic use

A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.

Enhanced bimatoprost ophthalmic solution

The present invention provides an aqueous ophthalmic solution with an effective amount of ketorolac and carboxymethyl cellulose in an aqueous solution which provides increased visual acuity and wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.

Ketorolac tromethamine compositions for treating or preventing ocular pain

Microparticles manufactured in an oil-in-water process comprising a prostamide

The present invention provides for compositions for administering a therapeutically effective amount of a therapeutic component. The compositions may include an ophthalmically acceptable carrier component; a therapeutically effective amount of a therapeutic component; and a retention component which may be effective to reduce wettability, induce viscosity, increase muco-adhesion, increase meniscus height on a cornea of an eye and/or increase physical apposition to a cornea of an eye of a composition.

Compositions for delivery of therapeutics into the eyes and methods for making and using same

Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

Growing community of inventors

Tustin, CA, United States of America

Chin-Ming Chang